Overview

Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)

Status:
Completed
Trial end date:
2019-11-05
Target enrollment:
Participant gender:
Summary
Open label, single arm study of intratumoral CVA21 and ipilimumab in advanced melanoma patients.
Phase:
Phase 1
Details
Lead Sponsor:
Viralytics
Collaborator:
Providence Health & Services
Treatments:
Antibodies, Monoclonal
Ipilimumab